Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers

Vaccine

Volumn 14, Issue 4, 1996, Pages 329-336

  Vaughn, David W ^e   Hoke Jr , Charles H ^a   Yoksan, Sutee ^b   LaChance, Rebecca ^c   Innis, Bruce L ^a   Rice, Robert M ^d   Bhamarapravati, Natth ^b  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^d Dept of Immunol and Molec Biology Bldg 1425 U States Army Med R   (United States)

^e NONE

Author keywords

clinical trial; dengue; live attenuated vaccines

Indexed keywords

DENGUE VACCINE; LIVE VACCINE;

ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; DENGUE; DRUG SAFETY; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION;

EID: 0029916970     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(95)00167-Y     Document Type: Article

References (14)

1. Brandt, W.E. From the World Health Organization. Development of dengue and Japanese encephalitis vaccines. J. Infect. Dis. 1990, 162, 577-583
2. Gubler, D.J. Aedes aegypti and Aedes aegypti-borne disease control in the 1990s: top down or bottom up. Charles Franklin Craig Lecture. Am. J. Trop. Med. Hyg. 1989, 40, 571-578
3. Bhamarapravati, N., Yoksan, S., Chayaniyayothin, T., Angsubphakorn, S. and Bunyaratvej, A. Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers. Bull. WHO 1987, 65, 189-195
4. Bhamarapravati, N. and Yoksan, S. Study of bivalent dengue vaccine in volunteers. Lancet 1989, 1, 1077
5. Innis, B.L., Nisalak, A., Nimmannitya, S. et al. An enzyme-linked immunosorbent assay to characterize dengue infections where dengue and Japanese encephalitis co-circulate. Am. J. Trop. Med. Hyg. 1989, 40, 418-427
6. Clarke, D.H. and Casals, J. Techniques for hemagglutination and hemagglutination inhibition with arthropod-borne viruses. Am. J. Trop. Med. Hyg. 1958, 7, 561-573
7. Gubler, D.J., Kuno, G., Sather, G.E., Velez, M. and Oliver, A. Mosquito cell cultures and specific monoclonal antibodies in surveillance for dengue viruses. Am. J. Trop. Med. Hyg. 1984, 33, 158-165
8. Rosen, L. The use of toxorhynchites mosquitoes to detect and propagate dengue and other arboviruses. Am. J. Trop. Med. Hyg. 1981, 30, 177-183
9. Rosen, L. and Shroyer, D.A. Comparative susceptibility of five species of Toxorhynchites mosquitoes to parenteral infection with dengue and other flaviviruses. Am. J. Trop. Med. Hyg. 1985, 34, 805-809
10. Kuberski, T., Rosen, L., Reed, D. and Mataika, J. Clinical and laboratory observatonson patients with primary and secondary dengue type 1 infections with hemorrhagic manifestations in Fiji. Am. J. Trop. Med. Hyg. 1977, 26, 775-783
11. Khin, M.M., Jirakanjanakit, N., Yoksan, S. and Bhamarapravati, N. Infection, dissemination, transmission, and biologcial attributes of dengue-2 PDK53 candidate vaccine virus after oral infection in Aedes aegypti. Am. J. Trop. Med. Hyg. 1994, 51, 864-869
12. Bravo, J.R., Guzman, M.G. and Kouri, G.P. Why dengue haemorrhagic fever in Cuba? 1. Individual risk factors for dengue haemorrhagic fever/dengue shock syndrome (DHF/ DSS). Trans. R. Soc. Trop. Med. Hyg. 1987, 81, 816-820
13. Bellanti, J.A., Bourke, R.T.A., Rosenzweig, E.C. and Eylar, O.R. Report of dengue vaccine trial in the Caribbean, 1963: a collaborative study. Bull. WHO 1966, 35, 93
14. Dharakul, T., Kurane, I., Bhamarapravati, N. et al. Dengue virus-specific memory T cell responses in human volunteers receiving a live attenuated dengue virus type 2 candidate vaccine. J. Infect. Dis. 1994, 170, 27-33